No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish pharmaceutical company has enacted a hiring freeze—the latest sign of a sinking financial outlook for the once-titan of the obesity treatment world.

“Semaglutide has been in the US for more than eight years now. In India also, the oral version of this molecule is there for more than 3 years. It is one of the most well studied compounds”, says Dr Shashank R Joshi, a Mumbai based endocrinologist and medical researcher.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Data to highlight the impact of Wegovy® (semaglutide 2.4 mg) on atrial fibrillation – a common heart rhythm condition – in people living with obesity (SELECT study)Additional Rybelsus® and Ozempic® da

The legal battle over Ozempic is getting bigger by the day. Multiple lawsuits have been filed against the diabetes-medicine-turned weight-loss drug. What started as scattered complaints has grown into more than a thousand lawsuits against Novo Nordisk.

After Novo Nordisk revealed Ozempic will retail for half-price at 70,000 pharmacies throughout the US, people are questioning its ethics